Charles River Poster Presentations
Charles River was proud to support the 2018 AACR Annual Meeting. Below, you can download any of our poster presentations covering a variety of research topics.
Sunday, April 15 | 1:00-5:00 p.m.
- Immune checkpoint inhibitor induced tumor gene expression changes in murine syngeneic colon cancer model
- Development and characterization of PDX-derived 3D tumor microtissues as platform for screening targeted molecular therapeutics (partnered with InSphero)
- Targeting the WNT-pathway in 3D-cultures of pancreatic cancer biopsies (partnered with Ocello)
Monday, April 16 | 8:00 a.m.-12:00 p.m.
- Identification of signal transduction pathway activity in patient-derived xenograft models in comparison with their originating clinical samples of a variety of human cancer types
- A translational platform using primary human immune cells in vitro, syngeneic and humanized models in vivo to support and advance immune-oncology drug discovery
- Therapeutic response to PD1/PDL1 axis in a disseminated C1498 Syngeneic Tumor Model
- Enhanced proliferation and effector functions of human immune cells in response to immune checkpoint therapy of MDA-MB-231 tumor bearing huNOG mice engrafted with human CD34+ cell
Monday, April 16 | 1:00-5:00 p.m.
Tuesday, April 17 | 8:00 a.m.-12:00 p.m.
- Quantitative measurement of immune-modulatory mediators within tumors of freely moving mice utilizing in vivo microdialysis
- Influence of targeted silencing of the BRCA1 gene on the pharmacological profile of the mouse breast cancer cell line EMT6 in vitro and in vivo
- Molecular, histopathologic, MRI and PET findings in syngeneic oncologic mouse models
Tuesday, April 17 | 1:00-5:00 p.m.
- Patient-derived 3D tumor cultures for clinical diagnostics and pre-clinical drug development (partnered with Ocello)
Wednesday, April 18 | 8:00 a.m.-12:00 p.m.
- Perfusion air culture of tissue slices: A new method to cultivate tumor tissue with minimal culture-dependent tissue stress
- Characterization of tumor growth and immune microenvironment in humanized NOG-EXL mice implanted with A549, MDA-MB-436 and A375 cells
Explore Some of Our Capabilities
Cancer drug discovery has advanced significantly in the last decade. The tool kits of drug discovery scientists are becoming increasingly more sophisticated and translational. Charles River is dedicated to guiding oncology researchers, leveraging our unmatched portfolio of in vitro and in vivo models and expertise in immunology, by providing a comprehensive offering of translational oncology discovery services.